This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen Regains Biotech Growth Cred With $10B Onyx Acquisition

THOUSAND OAKS, Calif. ( TheStreet) -- Investors appear to like Amgen's (AMGN - Get Report) decision to buy Onyx Pharmaceuticals (ONXX) for $10 billion. Amgen shares are up 9% to $114.65 in early Monday trading.

If you go back to June 28, when news of Amgen's interest in acquiring Onyx was first broken reported, the stock is up 16%.

By acquiring Onyx, Amgen earns back much-needed biotech street cred, which has been lost in recent years. Instead of growing earnings modestly through financial hocus-pocus -- share buybacks and expense cutting -- the addition of Onyx's multiple myeloma drug Kyrpolis will pump up Amgen's revenue growth, which will, of course, translate into higher earnings.

Even with Onyx, Amgen may still not have the earnings growth of Gilead Sciences (GILD - Get Report) or Celgene (CELG - Get Report) over the next 4-5 years, but it's better than the status quo.

Amgen says the Onyx deal will be neutral to earnings in 2014 and accretive starting in 2015, although the company hasn't provided more detailed projections. Amgen does plan to continue increasing its shareholder dividend over time.

ISI Group analyst Mark Schoenebaum forecasts the addition of Onyx revenue, mainly from Kyprolis, will boost Amgen's earnings by 5 percent in 2015, 10 percent in 2016 and 15 percent in 2017.

The Onyx deal also diversifies Amgen's revenue stream. At present, Amgen generates a a majority of its $17 billion-plus in annual revenue from drugs like Aranesp and Neulasta which help cancer patients better tolerate their treatments. Once the Onyx deal closes, Amgen will add a blockbuster multiple myeloma drug to its portfolio, making the company more of a significant player in drugs that treat cancer, not just the side effects of the disease.

Amgen has nine experimental drugs in late-stage clinical studies, including four novel cancer drugs. If anything of these pipeline drugs are approved, it will only add to the company's long-term growth and make the Onyx deal look that much smarter.

Over the past year, Amgen's stock price has underperformed its large-cap biotech peers, but that could change if investors begin to recognize the company once again as a biotech growth story. AMGN Chart AMGN data by YCharts

Risks? Absolutely. Right now, Kyprolis is only approved in the U.S. for multiple myeloma patients no longer responding to any other treatments. Onyx is conducting four additional clinical trials of Kyprolis aimed at getting the drug approved in Europe and demonstrating benefit for earlier-stage multiple myeloma patients. Much of these new clinical data will begin to roll in during the first half of 2014.

Today's positive verdict on the Amgen-Onyx deal will sour if Kyproplis is unable to gain European approval or make inroads into the more commercially lucrative, early-stage multiple myeloma treatment markets.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
AMGN $149.59 0.00%
CELG $117.38 0.00%
GILD $100.65 0.00%
AAPL $112.12 0.00%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs